KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5155 in its research report dated May 12, 2023.
Prabhudas Lilladher recommended Reduce rating on Dr. Reddy's Laboratories with a target price of Rs 4500 in its research report dated May 11, 2023.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated January 27, 2023.
ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 5210 in its research report dated January 27, 2023.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated January 25, 2023.
EMs are expected to remain the chief driver of top-line growth, driven by chronic therapies and biosimilars
The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated December 21, 2022.
Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 5180 in its research report dated October 29, 2022.
ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 5215 in its research report dated October 29, 2022.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated October 31, 2022.
Emerging markets, including India, would remain the chief driver of top-line growth
KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 4869 in its research report dated July 29, 2022.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4750 in its research report dated July 29, 2022.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 28, 2022.
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4750 in its research report dated July 29, 2022.
KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5261 in its research report dated July 12, 2022.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated June 22, 2022.
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4960 in its research report dated June 22, 2022.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated June 22, 2022.
KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5261 in its research report dated May 23, 2022.
The company’s success depends on identifying the molecule/product opportunity, investing behind R&D and implementing processes/integration to scale it up
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, 2022.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated May 19, 2022.
Motilal Oswal is bullish on Dr Reddy’s Labs recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, 2022.